E Fund Management Co. Ltd. Purchases 1,508 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

E Fund Management Co. Ltd. boosted its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 74.6% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 3,530 shares of the medical equipment provider’s stock after purchasing an additional 1,508 shares during the period. E Fund Management Co. Ltd.’s holdings in Zimmer Biomet were worth $373,000 as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of the company. Candriam S.C.A. lifted its stake in Zimmer Biomet by 24.9% in the 4th quarter. Candriam S.C.A. now owns 21,769 shares of the medical equipment provider’s stock valued at $2,299,000 after purchasing an additional 4,336 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in Zimmer Biomet in the 4th quarter valued at about $21,234,000. Arizona State Retirement System lifted its stake in Zimmer Biomet by 0.4% in the 4th quarter. Arizona State Retirement System now owns 59,152 shares of the medical equipment provider’s stock valued at $6,248,000 after purchasing an additional 211 shares during the last quarter. Proficio Capital Partners LLC acquired a new stake in Zimmer Biomet in the 4th quarter valued at about $55,000. Finally, M&T Bank Corp lifted its stake in Zimmer Biomet by 0.4% in the 4th quarter. M&T Bank Corp now owns 26,827 shares of the medical equipment provider’s stock valued at $2,834,000 after purchasing an additional 108 shares during the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the transaction, the senior vice president now directly owns 8,768 shares of the company’s stock, valued at $915,379.20. This trade represents a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.95% of the stock is currently owned by insiders.

Zimmer Biomet Stock Up 2.4 %

Shares of ZBH opened at $107.87 on Friday. The firm’s 50 day moving average is $105.55 and its 200-day moving average is $107.19. The stock has a market capitalization of $21.47 billion, a PE ratio of 24.24, a P/E/G ratio of 1.95 and a beta of 1.04. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. Zimmer Biomet Holdings, Inc. has a 12 month low of $97.69 and a 12 month high of $133.90.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period in the previous year, the business earned $2.20 EPS. Equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a $0.24 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a yield of 0.89%. Zimmer Biomet’s dividend payout ratio (DPR) is 21.57%.

Wall Street Analyst Weigh In

ZBH has been the subject of several recent analyst reports. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Stifel Nicolaus raised their price objective on shares of Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a research report on Thursday, January 23rd. Barclays cut their price objective on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a research report on Monday, February 10th. JMP Securities restated a “market outperform” rating and set a $140.00 price objective on shares of Zimmer Biomet in a research report on Friday, February 7th. Finally, JPMorgan Chase & Co. upgraded shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $125.00 to $128.00 in a research report on Tuesday, December 17th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $124.15.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.